Does Rallies show Form 4 insider transactions for AXGN?

Yes. Rallies tracks AXGN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is AXGN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AXGN. It does not provide personalized investment advice.

AXGN (Axogen, Inc. Common Stock) Stock Analysis - Insider Trades

Axogen, Inc. Common Stock (AXGN) is a publicly traded Healthcare sector company. As of May 21, 2026, AXGN trades at $42.94 with a market cap of $2.23B and a P/E ratio of -67.85. AXGN moved -0.07% today. Year to date, AXGN is +34.41%; over the trailing twelve months it is +268.97%. Its 52-week range spans $9.22 to $45.83. Analyst consensus is strong buy with an average price target of $50.14. Rallies surfaces AXGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading AXGN stock inside the company?

Recent AXGN insider activity includes JOHNSON JOHN sold 11.05K, Weiler Kathy Johnson sold 16.34K, Kemp Jens sold 4.00K, Hartley Lindsey Marie sold 478, and Hartley Lindsey Marie sold 573. Rallies tracks insider transaction dates, shares, prices, and estimated values.

AXGN Key Metrics

Key financial metrics for AXGN
Metric	Value
Price	$42.94
Market Cap	$2.23B
P/E Ratio	-67.85
EPS	$-0.63
Dividend Yield	1.00%
52-Week High	$45.83
52-Week Low	$9.22
Volume	32
Avg Volume	0
Revenue (TTM)	$238.10M
Net Income	$-31.45M
Gross Margin	75.01%

Recent AXGN Insider Trades

JOHNSON JOHN sold 11.05K (~$477.97K) on May 7, 2026.
Weiler Kathy Johnson sold 16.34K (~$720.62K) on May 7, 2026.
Kemp Jens sold 4.00K (~$173.76K) on May 7, 2026.
Hartley Lindsey Marie sold 478 (~$20.87K) on May 7, 2026.
Hartley Lindsey Marie sold 573 (~$25.02K) on May 7, 2026.

Latest AXGN News

Axogen Reports 26.6% Q1 Revenue Growth to $61.5M, Guides $270M in 2026 — Apr 29, 2026
Axogen Secures FDA Approval with 12-Year Exclusivity, Posts 20% Q4 Revenue Growth — Feb 19, 2026
Axogen CEO Sells $750K Shares, Cuts Direct Holdings by 28% — Jan 15, 2026

AXGN Analyst Consensus

7 analysts cover AXGN: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $50.14.

Common questions about AXGN

Who is trading AXGN stock inside the company?: Recent AXGN insider activity includes JOHNSON JOHN sold 11.05K, Weiler Kathy Johnson sold 16.34K, Kemp Jens sold 4.00K, Hartley Lindsey Marie sold 478, and Hartley Lindsey Marie sold 573. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for AXGN?: Yes. Rallies tracks AXGN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is AXGN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AXGN. It does not provide personalized investment advice.